PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Arjun Balar, MD - Advancing Bladder Cancer Care With Novel Therapeutics: Where We Are Headed With Immunotherapy, Targeted, and Antibody Options
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.